Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

• Status: Recruiting
• Trial end date: 2025-12-01

Summary

This is a multicenter, single arm, open-label, Phase 2 study in mutiple myeloma with newly diagnosed and treatment-naïve participants for whom high-dose therapy and autologous stem cell transplantation is part of the intended treatment plan. The study is evaluating a technique called Mass Spectrometry Minimal Residual Disease (MS-MRD) using blood samples and compares it with the minimal residual disease (MRD) technique using bone marrow samples.

• Phase: Phase 2

Details

• Lead Sponsor: Stichting European Myeloma Network
• Collaborator: Janssen Pharmaceutica
• Treatments: Bortezomib; Daratumumab; Dexamethasone; Lenalidomide